Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biotest acquiring Nabi's biologics unit

Biotest (FSE:BIO) will acquire NABI's Nabi Biologics group for $185 million in cash. BIO said the group complements its European plasma protein business and gives it

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE